Big Money Are Buying Aveo Pharmaceuticals Inc (NASDAQ:AVEO), Sentiment at 2.81
May 12, 2018 - By Andrea Pope
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Corporate Logo
“Big money” Positions
“Big money sentiment for Aveo Pharmaceuticals Inc (NASDAQ:AVEO) in Q4 2017 increased to 2.81, SEC.gov filings reveal. So its up 1.49, from 2017Q3’s 1.32. 45 funds increased or started new holdings, while 16 sold and decreased positions in Aveo Pharmaceuticals Inc so the sentiment is better. These funds own 59.55 million shares, that’s down from 59.90 million shares in 2017Q3. Funds holding Aveo Pharmaceuticals Inc in top 10 changed to 1 from 3 for a decrease of 2. 4 Investors Sold All; 12 Reduced Holdings; 19 increased stakes while 26 funds bought stakes.
Significant Aveo Pharmaceuticals Inc Investors
As of Q4 2017 Deer Vi & Co. Llc has 100% invested in Aveo Pharmaceuticals Inc. Aveo Pharmaceuticals Inc’s shareholder Nea Management Company Llc owns 16.36 million shares as of Q4 2017. Furthermore, Emory University reported 602,883 shares in Aveo Pharmaceuticals Inc equivalent to 1.44% of its portfolio. New Leaf Venture Partners L.L.C. revealed 964,520 shares position in Aveo Pharmaceuticals Inc. The Massachusetts-based fund Ra Capital Management Llc looks positive on Aveo Pharmaceuticals Inc, owning 5.06 million shares.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases.The firm is valued at $334.51 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.Last it reported negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.
AVEO is hitting $2.17 during the last trading session, after decreased 2.25%.AVEO Pharmaceuticals, Inc. has volume of 1.01 million shares. Since May 12, 2017 AVEO has risen 351.31% and is uptrending. The stock outperformed the S&P 500 by 339.76%.
Spark Investment Management Limited Liability Company holds 0.04% or 268,200 shs. Bank Of Ny Mellon reported 91,625 shs or 0% of all its holdings. Bridgeway Cap Mgmt invested in 346,464 shs or 0.01% of the stock. Grimes And reported 22,600 shs or 0.01% of all its holdings. Schwab Charles Inv owns 28,629 shs. Atlantic Gp Ltd Com owns 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2,000 shs. The Florida-based Finemark Financial Bank Tru has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Susquehanna Intl Grp Llp holds 0% or 292,692 shs in its capital. 1.88M were accumulated by Blackrock Inc. Citigroup Inc reported 2,679 shs or 0% of all its holdings. Essex Mgmt Co Ltd Liability has invested 0.07% of its capital in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Moreover, Vanguard Gp has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Tower Rech Capital Ltd Limited Liability Company (Trc) invested 0.01% of its capital in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Eam Lc owns 626,499 shs or 0.23% of their US capital. Citadel Advsr Limited Liability Company reported 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO).
AVEO Pharmaceuticals, Inc. registered $21.15 million net activity with 10 insider purchases and 0 sales since April 6, 2018. On Friday, April 6 MOTT DAVID M bought $2.12 million worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 920,976 shs. BASKETT FOREST had bought 920,976 shs worth $2.12M. 920,976 shs valued at $2.12 million were bought by Viswanathan Ravi on Friday, April 6. $2.12 million worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by MAKOWER JOSHUA. On Friday, April 6 $2.12M worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by BARRIS PETER J. Sakoda Jon also bought $2.12 million worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shs.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage
In total 2 analysts cover AVEO Pharma (NASDAQ:AVEO). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $5.0 highest and $500 lowest target AVEO Pharma has $5 average target or 130.41% above the current ($2.17) price. 7 are the (NASDAQ:AVEO)’s analyst reports since November 13, 2017 according to StockzIntelligence Inc. On Thursday, March 22 the firm has “Buy” rating by FBR Capital given. On Tuesday, January 16 the firm has “Buy” rating given by FBR Capital. On Monday, February 12 FBR Capital maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) with “Buy” rating. In Thursday, December 7 report FBR Capital maintained the stock with “Buy” rating. On Tuesday, March 13 the firm has “Buy” rating by FBR Capital given. On Thursday, March 29 the stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by Piper Jaffray.
More recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were announced by Nasdaq.com, Seekingalpha.com and Nasdaq.com. The first one has “Here’s Why AVEO Pharmaceuticals Fell as Much as 17% Today” as a title and was announced on May 08, 2018. The next is “3 Things In Biotech, May 9: New AML Therapy Imminent? AVEO Hedges, Rockwell Boosts Iron” on May 10, 2018. And last was announced on May 09, 2018, called “Factors of Influence in 2018, Key Indicators and Opportunity within FNB, Comcast, IZEA, AVEO Pharmaceuticals …”.
